Applying control system modelling to understand how genetic variation influences serotonin function and behavior

Neural Synapse Research Trends

Volumn , Issue , 2007, Pages 133-171

  Stoltenberg, Scott F ^a   Nag, Parthasarathi ^a  

^a BLACK HILLS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949265087     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (90)

1. Weiger WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev Camb Philos Soc 1997;72(1):61-95.
2. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44(3):151-62.
3. Baumgarten HG, Grozdanovic Z. Anatomy of Central Serotonergic Projection Systems. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer-Verlag; 1999.
4. Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry 1992;53 Suppl:3-7.
5. Veenstra-VanderWeele J, Anderson GM, Cook EH, Jr. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000;410(2- 3):165-181.
6. Bell CJ, Hood SD, Nutt DJ. Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry 2005;39(7):565-74.
7. Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry 2005;39(7):558-64.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision ed. Washington, DC: Author 2000.
9. Marek GJ, Duman RS. Neural Circuitry and Signalling in Depression. In: Kaplan GB, Hammer RP, editors. Brain Circuitry and Signalling in Psychiatry: Basic Science and Clinical Implications. Washington, D.C.: American Psychiatric Publishing, Inc.; 2002. p. 153-178.
10. Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006;14(6):660-8.
11. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301(5631):386-9.
12. Gorman JM, Kent JM, Coplan JD. Current and Emerging Therapeutics of Anxiety and Stress Disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff CB, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott, Williams and Wilkins; 2002. p. 967-980.
13. Leonardo ED, Hen R. Genetics of affective and anxiety disorders. Annu Rev Psychol 2006;57:117-37.
14. Hammer RP. Neural Circuitry and Signaling in Addiction. In: Kaplan GB, Hammer RP, editors. Brain Circuitry and Signaling in Psychiatry. Washington, D.C.: American Psychiatric Publishing, Inc.; 2002. p. 99-124.
15. Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 2001;25(4):487-95.
16. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005;6(7):521-32.
17. Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004;18(15):1105-18.
18. Potenza MN, Hollander E. Pathologic Gambling and Impulse Control Disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff CB, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippencott, Williams and Wilkins; 2002. p. 1725-1741.
19. Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004;16(1):27-34.
20. Ibanez A, Blanco C, de Castro IP, Fernandez-Piqueras J, Saiz-Ruiz J. Genetics of pathological gambling. J Gambl Stud 2003;19(1):11-22.
21. Heckers S, Goff DC. Neural Circuitry and Signaling in Schizophrenia. In: Kaplan GB, Hammer RP, editors. Brain Circuitry and Signaling in Psychiatry. Washington, D.C.: American Psychiatric Publishing, Inc.; 2002. p. 67-97.
22. Vaquero Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Botillo-Martin C, Perez-Rodriguez MM, Fernandez-Ramos C, et al. Association between the T102C polymorphism of the serotonin-2A receptor gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(6):1136-8.
23. Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004;18(3):340-5.
24. Nichols DE. Role of Serotonergic Neurons and 5-HT Receptors in the Action of Hallucinogens. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999. p. 563-585.
25. KayeWH, Frank GK, Bailer UF, Henry SE,Meltzer CC, Price JC, et al. Serotonin alterations in anorexia and bulimia nervosa: new insights fromimaging studies. Physiol Behav 2005;85(1):73-81.
26. Klump KL, Gobrogge KL. A review and primer of molecular genetic studies of anorexia nervosa. Int J Eat Disord 2005;37 Suppl:S43-8; discussion S87-9.
27. Fairburn CG. Evidence-based treatment of anorexia nervosa. Int J Eat Disord 2005;37 Suppl:S26-30; discussion S41-2.
28. Steffen KJ, Roerig JL, Mitchell JE, Uppala S. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs 2006;11(2):315-36.
29. Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999.
30. Lesch K-P. Molecular Biology, Pharmacology, and Genetics of the Serotonin Transporter: Psychobiological and Clinical Implications. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999. p. 671-705.
31. Gobbi G, Murphy DL, Lesch K, Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 2001;296(3):987-95.
32. Mannoury la Cour C, Boni C, Hanoun N, Lesch KP, Hamon M, Lanfumey L. Functional consequences of 5-HT transporter gene disruption on 5-HT1A receptormediated regulation of dorsal raphe and hippocampal cell activity. J Neurosci 2001;21(6):2178-85.
33. Evrard A, Laporte AM, Chastanet M, Hen R, Hamon M, Adrien J. 5-HT1A and 5-HT1B receptors control the firing of serotoninergic neurons in the dorsal raphe nucleus of the mouse: studies in 5-HT1B knock-out mice. Eur J Neurosci 1999;11(11):3823-31.
34. Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci U S A 2006;103(21):8233-8.
35. Stoltenberg SF, Burmeister M. Recent progress in psychiatric genetics-some hope but no hype. Hum Mol Genet 2000;9(6):927-35.
36. Levinson DF. The genetics of depression: a review. Biol Psychiatry 2006;60(2):84-92.
37. Hariri AR, Holmes A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 2006;10(4):182-91.
38. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6(1):27-33.
39. Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006;11(4):336-51.
40. Feinn R, Nellissery M, Kranzler HR. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2005;133(1):79-84.
41. Li J, Wang Y, Zhou R, Zhang H, Yang L, Wang B, et al. Association between polymorphisms in serotonin transporter gene and attention deficit hyperactivity disorder in Chinese Han subjects. Am J Med Genet B Neuropsychiatr Genet 2006.
42. Frieling H, Romer KD, Wilhelm J, Hillemacher T, Kornhuber J, de Zwaan M, et al. Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. Psychiatr Genet 2006;16(5):205-8.
43. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004;127(1):85-9.
44. Gothert M, Schlicker E. Regulation of 5-HT Release in the CNS by Presynaptic 5- HT Autoreceptors and by 5-HT Heteroreceptors. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999. p. 307-350.
45. Toth M. 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur J Pharmacol 2003;463(1-3):177-84.
46. Richer M, Hen R, Blier P.Modification of serotonin neuron properties in mice lacking 5-HT1A receptors. Eur J Pharmacol 2002;435(2-3):195-203.
47. He M, Sibille E, Benjamin D, Toth M, Shippenberg T. Differential effects of 5-HT1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis. Brain Res 2001;902(1):11-7.
48. Parsons LH, Kerr TM, Tecott LH. 5-HT1A receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission. J Neurochem 2001;77(2):607-17.
49. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, Zeng Y, et al. Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J Neural Transm 2003;110(12):1445-53.
50. Huang YY, Battistuzzi C, Oquendo MA, Harkavy-Friedman J, Greenhill L, Zalsman G, et al. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol 2004;7(4):441-51.
51. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001;21(1):36-45.
52. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7(2):139-47.
53. de Groote L, Olivier B, Westenberg HG. Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT1B autoreceptors: a microdialysis study in knockout mice. Psychopharmacology (Berl) 2002;162(4):419-24.
54. Crabbe JC, Phillips TJ, Feller DJ, Hen R, Wenger CD, Lessov CN, et al. Elevated alcohol consumption in null mutant mice lacking 5-HT1B serotonin receptors. Nat Genet 1996;14(1):98-101.
55. Lappalainen J, Long JC, EggertM, Ozaki N, Robin RW, Brown GL, et al. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry 1998;55(11):989-94.
56. Joh TH. Tryptophan Hydroxylase: Molecular Biology and Regulation. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999. p. 117-129.
57. Veenstra-VanderWeele J, Cook EH, Jr. Knockout mouse points to second form of tryptophan hydroxylase. Mol Interv 2003;3(2):72-5.
58. Stoltenberg SF, Glass JM, Chermack ST, Flynn HA, Li S,Weston ME, et al. Possible association between response inhibition and a variant in the brain-expressed tryptophan hydroxylase gene (TPH2). Psychiatric Genetics 2006;16:35-38.
59. Shih JC, Grimsby J, Chen K. Molecular Biology of Monoamine OxidaseA and B: Their Role in the Degredation of Serotonin. In: Baumgarten HG, Gothert M, editors. Serotonergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer; 1999. p. 655-670.
60. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7(4):295-309.
61. Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 1991;49(2):383-92.
62. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002;297(5582):851-4.
63. Hirsch J. Behavior-Genetic Analysis. In: Hirsch J, editor. Behavior-Genetic Analysis. New York: McGraw Hill; 1967. p. 416-435.
64. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001;2:343-72.
65. Stoltenberg SF. Epistasis among presynaptic serotonergic system components. Behavior Genetics 2005;35(2):199-209.
66. Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept-an hypothesis. Alcohol Clin Exp Res 2000;24(10):1597-601.
67. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berl) 2000;149(4):327-44.
68. Stoltenberg SF. Serotonergic agents and alcoholism treatment: A simulation. Alcoholism-Clinical And Experimental Research 2003;27(12):1853-1859.
69. Marsh AA, Finger EC, Buzas B, Soliman N, Richell RA, Vythilingham M, et al. Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion. Psychopharmacology (Berl) 2006.
70. Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006;63(9):978-86.
71. Kim-Cohen J, Caspi A, Taylor A,Williams B, Newcombe R, Craig IW, et al. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry 2006;11(10):903-13.
72. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, et al. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 2003;28(3):533-41.
73. Gerald MS, Higley JD. Evolutionary underpinnings of excessive alcohol consumption. Addiction 2002;(4):415-25.
74. Fister KR, Panetta JC. Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy. SIAM Journal of Applied Mathematics 2000;60:1059-1072.
75. Bacciotti A. Local Stabilizability of Nonlinear Control Systems. Singapore: World Scientific; 1992.
76. Ross KA. Elementary Analysis: The Theory of Calculus. 1 ed: Springer; 1980.
77. Rudin W. Principles of Mathematical Analysis. 3 ed: McGraw Hill; 1976.
78. Perko L. Differential Equations and Dynamical Systems. New York, NY: Springer- Verlag; 1991.
79. Royden HL. Real Analysis. 3 ed. NJ: Prentice Hall; 1988.
80. Khalil HK. Nonlinear Systems. Upper Saddle River, NJ: Prentice Hall; 1996.
81. Rugh WJ. Linear System Theory. Upper Saddle River, NJ: Prentice Hall; 1996.
82. Nijmeijer H, van der Schaft AJ. Nonlinear Dynamical Control Systems. New York, NY: Springer-Verlag; 1995.
83. Jurdjevic V. Geometric Control Theory. New York, NY: Cambridge University Press; 1997.
84. Jurdjevic V, Sussman HJ. Controllability of Nonlinear Systems. Journal of Differential Equations 1972;12:95-116.
85. Jurdjevic V. and H. J. Sussmann, Controllability of Nonlinear Systems, Journal of Differential Equations, 1972;12:95-116.
86. Sastry, S.S., Nonlinear Systems, Springer-Verlag, 1999, 10, Interdisciplinary Applied Mathematics, NY.
87. Munkres, J.R., Topology, Prentice Hall,1996, Upper Saddle River, NJ 07458.
88. Bloch, A.M., Nonholonomic Mechanics and Control, Springer-Verlag, 2003, 24, Interdisciplinary Applied Mathematics, NY.
89. Plomin R, DeFries JC, Craig IW, McGuffin P. Behavioral Genomics. In: Plomin R, DeFries JC, Craig IW, McGuffin P, editors. Behavioral Genetics in the Postgenomic Era. Washington, D.C.: American Psychological Association; 2003. p. 531-540.
90. Lerer B, editor. Pharmacogenetics of Pscyhotropic Drugs. Cambridge, U.K.: Cambridge University Press; 2002.